163 related articles for article (PubMed ID: 29702736)
1. Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Liu T; Ivaturi V; Sabato P; Gobburu JVS; Greer JM; Wright JJ; Smith BD; Pratz KW; Rudek MA;
Clin Transl Sci; 2018 Jul; 11(4):435-443. PubMed ID: 29702736
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
5. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
6. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR; Baumgartner F; Braun L; O'Sullivan D; Thomas S; Waterhouse M; Müller TA; Hanke K; Taromi S; Apostolova P; Illert AL; Melchinger W; Duquesne S; Schmitt-Graeff A; Osswald L; Yan KL; Weber A; Tugues S; Spath S; Pfeifer D; Follo M; Claus R; Lübbert M; Rummelt C; Bertz H; Wäsch R; Haag J; Schmidts A; Schultheiss M; Bettinger D; Thimme R; Ullrich E; Tanriver Y; Vuong GL; Arnold R; Hemmati P; Wolf D; Ditschkowski M; Jilg C; Wilhelm K; Leiber C; Gerull S; Halter J; Lengerke C; Pabst T; Schroeder T; Kobbe G; Rösler W; Doostkam S; Meckel S; Stabla K; Metzelder SK; Halbach S; Brummer T; Hu Z; Dengjel J; Hackanson B; Schmid C; Holtick U; Scheid C; Spyridonidis A; Stölzel F; Ordemann R; Müller LP; Sicre-de-Fontbrune F; Ihorst G; Kuball J; Ehlert JE; Feger D; Wagner EM; Cahn JY; Schnell J; Kuchenbauer F; Bunjes D; Chakraverty R; Richardson S; Gill S; Kröger N; Ayuk F; Vago L; Ciceri F; Müller AM; Kondo T; Teshima T; Klaeger S; Kuster B; Kim DDH; Weisdorf D; van der Velden W; Dörfel D; Bethge W; Hilgendorf I; Hochhaus A; Andrieux G; Börries M; Busch H; Magenau J; Reddy P; Labopin M; Antin JH; Henden AS; Hill GR; Kennedy GA; Bar M; Sarma A; McLornan D; Mufti G; Oran B; Rezvani K; Shah O; Negrin RS; Nagler A; Prinz M; Burchert A; Neubauer A; Beelen D; Mackensen A; von Bubnoff N; Herr W; Becher B; Socié G; Caligiuri MA; Ruggiero E; Bonini C; Häcker G; Duyster J; Finke J; Pearce E; Blazar BR; Zeiser R
Nat Med; 2018 Mar; 24(3):282-291. PubMed ID: 29431743
[TBL] [Abstract][Full Text] [Related]
10. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
11. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
[TBL] [Abstract][Full Text] [Related]
12. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Xuan L; Wang Y; Huang F; Fan Z; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Yu C; Zhou X; Lin R; Chen Y; Tu S; Huang X; Liu Q
Lancet Oncol; 2020 Sep; 21(9):1201-1212. PubMed ID: 32791048
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
16. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
[TBL] [Abstract][Full Text] [Related]
17. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Metzelder SK; Schroeder T; Finck A; Scholl S; Fey M; Götze K; Linn YC; Kröger M; Reiter A; Salih HR; Heinicke T; Stuhlmann R; Müller L; Giagounidis A; Meyer RG; Brugger W; Vöhringer M; Dreger P; Mori M; Basara N; Schäfer-Eckart K; Schultheis B; Baldus C; Neubauer A; Burchert A
Leukemia; 2012 Nov; 26(11):2353-9. PubMed ID: 22504140
[TBL] [Abstract][Full Text] [Related]
18. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
19. Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia.
Freyer CW; Mangan JK
J Oncol Pharm Pract; 2019 Dec; 25(8):2035-2037. PubMed ID: 30537918
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
